Sign up for the QMED & MD+DI Daily newsletter.
Inhaled Insulin Patent Dispute Settled
Novo Nordisk and Pfizer announced that they have settled Novo Nordisk's lawsuit alleging Pfizer's Exubera violated its patents for inhaled insulin, Reuters News reports. Terms were not available. The product had remained on the market after a judge cited patient needs in denying Novo Nordisk's request to require its withdrawal. This closes the book on Pfizer's involvement with the much-hyped Exubera.
December 11, 2007
1 Min Read
.svg?width=1280&auto=webp&quality=95&format=jpg&disable=upscale "MDDI")
After the product failed to get much of a foothold on the market, the drug giant returned its rights to its co-developer, Nektar Therapeutics. It also paid Nektar $135 million to settle a contract dispute related to Exubera. Let's hope Nektar can do a better job marketing it than Pfizer did.
You May Also Like
.png?width=300&auto=webp&quality=80&disable=upscale)
.png?width=300&auto=webp&quality=80&disable=upscale)
.png?width=300&auto=webp&quality=80&disable=upscale)